BDH Peer Comparison

NSE: MBIND | BSE: 524828

₹513.35

₹-14.90 (-2.82%)

As on 28-Aug-2026IST

Market cap

₹296 Cr

Revenue (TTM)

₹100 Cr

P/E Ratio

25.2

P/B Ratio

3.8

Div. Yield

1 %

Edit

	BDH	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Market cap (₹ Cr)	296	21,501	19,125	18,253	17,766
Revenue (₹ Cr)	100	2,570	2,287	3,230	2,432
Net Profit (₹ Cr)	11.71	735.15	678.07	666.92	169.62
Net Margin (%)	11.50	26.88	28.10	20.60	6.90
RoE (%)	15.86	19.16	19.73	18.75	20.76
Price to Earnings	25.24	29.25	28.74	28.35	104.74
Price-To-Book	3.77	4.88	5.08	4.51	19.65

Income Statement (₹ Cr)

	BDH	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Operating Revenue	95.95	2,519.65	1,937.47	2,893.64	2,275.58
Total Income	98.20	2,707.60	2,033.90	2,912.00	2,304.07
Total Expenditure	82.08	1,615.47	1,290.54	1,876.44	2,013.55
EBITDA	13.88	904.18	646.93	1,017.20	262.03
Depreciation	0.87	57.73	65.96	315.46	28.58
EBIT	13.01	846.45	580.97	701.74	233.45
Interest	0.06	9.57	0.61	231.29	4.49
Other Income	2.24	187.95	96.43	18.36	28.49
Exceptional Items	--	-49.16	--	--	-5.25
Profit before Tax	15.19	975.67	676.78	488.87	252.20
Provision for Tax	4.38	253.24	135.69	114.20	64.68
Profit after Tax	10.81	722.43	541.09	374.67	187.52

	BDH	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Shareholder's Funds	77.01	4,202.90	2,850.49	2,854.36	872.79
Minority Interest	--	--	35.90	417.40	--
Non-Current Liabilities	2.10	19.19	13.24	2,100.97	394.49
Current Liabilities	19.97	627.48	305.99	1,489.55	1,109.50
Total Liabilities	99.09	4,921.88	3,207.85	6,862.28	2,414.58

	BDH	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Non-Current Assets	19.29	1,046.35	1,071.67	5,531.13	509.16
Current Assets	79.80	3,803.22	2,133.95	1,331.15	1,859.88
Total Assets	99.09	4,921.88	3,207.85	6,862.28	2,414.58
Total Debt*	2.02	2.50	0.55	2,421.66	0.00
Net Current Assets	59.82	3,175.74	1,827.96	-158.40	750.38
Contingent Liabilities	0.12	370.49	0.64	64.29	121.23

	BDH	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Cash From Operating Activities	-2.41	967.57	432.37	1,065.01	-15.14
Cash Flow from Investing Activities	2.22	-561.67	-334.73	-79.97	18.69
Cash from Financing Activities	-1.61	-798.31	-38.32	-881.32	-91.97
Net Cash Inflow / Outflow	-1.81	-392.41	59.32	103.72	-88.42

	BDH	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
ROCE (%)	20.88	23.39	26.22	13.59	31.24
ROE (%)	15.11	17.16	21.72	13.81	23.02
ROA (%)	11.63	14.91	18.37	5.48	8.90
EBIT Margin (%)	16.80	43.34	38.37	35.79	12.77
Net Margin (%)	11.01	26.68	26.60	12.87	8.14
Cash Profit Margin (%)	12.17	29.72	31.33	23.22	9.47

	BDH	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Revenue Growth (%)	44.27	10.45	14.37	44.02	32.59
EBIT Growth (%)	19.90	19.68	20.21	48.22	-1.38
Net Profit Growth (%)	16.61	-5.88	17.27	-5.65	62.02
EPS Growth (%)	16.61	-5.88	17.25	-10.39	62.02
Book Value Growth (%)	12.24	-0.34	23.77	10.19	13.51

	BDH	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Price / Earnings	18.78	29.89	28.38	54.83	103.45
Price / Book Value	2.68	5.14	5.52	6.78	22.39
Dividend Yield (%)	1.42	1.59	0.30	0.52	0.46
EV/EBITDA	10.90	16.93	19.78	20.75	65.23
Market Cap (₹ Cr)	203.06	21,592.90	15,219.80	19,292.77	19,398.64

	BDH	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Debt to Equity	0.03	0.00	0.00	0.85	0.00
Short term debt to equity ratio	0.03	0.00	0.00	0.14	--
Current Ratio	4.00	6.06	6.97	0.89	1.68
Quick Ratio	3.73	5.31	5.88	0.67	0.75
Interest Coverage	250.49	102.95	1,110.48	3.11	57.17

	BDH	Pfizer	Caplin Point Lab	Eris Lifesciences	Astrazeneca Pharma
Debtors to sales (%)	32.94	7.22	32.65	15.85	9.39
Asset Turnover	1.03	0.54	0.66	0.43	1.08
Receivable days	87.10	26.06	110.70	54.07	31.88
Inventory Days	24.27	65.95	65.86	32.16	126.03
Payable days	89.90	81.01	105.88	140.91	163.79
Cash Conversion Cycle	21.47	11.00	70.68	-54.68	-5.88

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.